Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish

Life Sci. 2023 Sep 15:329:121956. doi: 10.1016/j.lfs.2023.121956. Epub 2023 Jul 19.

Abstract

Escherichia coli Nissle 1917 (EcN) has become a research hotspot in inflammatory bowel disease (IBD). It has a strong targeting effect on the colon, and has some therapeutic effect on inflammatory bowel disease. EcN is prepared into EcN ghosts, which also retain EcN's biological characteristics. Consequently, EcN ghosts are used for drug delivery. This study evaluated the safety and efficacy of EcN ghosts as carriers of drugs for treating IBD in zebrafish. Caco-2 cell adhesion experiments and zebrafish intestinal adhesion experiments demonstrated that EcN ghosts was highly adherent to the intestine. Additionally, oral administration of EcN ghosts attenuated dextran sulfate sodium-induced IBD symptoms by inhibiting neutrophil chemotaxis and reactive oxygen species production in larval zebrafish. Because of the unique biological functions of EcN ghosts, it may serve as a strategy for future targeted drug delivery in IBD treatment.

Keywords: Bacterial ghosts; Drug delivery system; Escherichia coli Nissle 1917; Inflammatory bowel disease; Zebrafish.

MeSH terms

  • Animals
  • Caco-2 Cells
  • Escherichia coli
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Intestines
  • Probiotics*
  • Zebrafish